Finding and working with Angels & Angel Groups in Life Sciences
May 4, 2021 11:00 a.m. PT
Register Here
California and the Boston/NY Corridor offer sector investing in medtech, diagnostics tools and instruments, and biotech. Other hubs of life science investing exist but are more localized in focus. How can you identify and access the right investors for your life science startup? How can you form an investment syndicate with the total cash needed to hit milestones and deliverables that will significantly increase your enterprise value for existing and follow on investors? How should you think about valuation and what should you expect by way of dilution? Brought to you through our partnership with Brex. Learn more about Brex and our Bio Business Solutions program here.
Allan is a co-founder of Life Science Angels, the largest and most well-known early-stage investment group focused solely on emerging biotech, genomic, medical device, diagnostic and mobile health companies (LSA). LSA has invested over $70M in 65 portfolio companies and achieved 23 positive exits, and was named the Top Angel Investment Group in the United States by industry analytical source CB Insights. In 2018, Allan co-founded Woodside Medical, an incubator helping commercialize U.S. medical technologies in China. In 2020, Allan joined the Medtech Convergence Fund as a Venture Partner. MCF is focused on the shift in therapy from intervention to prevention, invasive to non-invasive, and hospitals to the home, improving patient access while lowering the costs of managing disease. Allan is also Chairman of FundamentalVR.
